New combo therapy targets tough lung cancers
Disease control
Not yet recruiting
This study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find th…
Phase: PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC